MEMO FROM THE FUTURE: VETERINARY PRODUCT COMPANIES

The Disruption of Pharma, Diagnostics, Equipment, and Nutrition

Preface: This document is a speculative macro memo written from June 30, 2030, examining the disruption of product markets in veterinary medicine. It addresses product companies selling to veterinary practices — pharmaceutical companies (Zoetis, Elanco), diagnostic manufacturers (IDEXX, Covetrus), equipment manufacturers, and pet nutrition companies (Hill's, Royal Canin). It is a thought experiment, not a prediction, and should be read as rigorous fiction. This memo addresses product company executives, sales leaders, and strategy teams across these sectors.

SUMMARY: THE BEAR CASE vs. THE BULL CASE

Bear case: veterinary pharmaceutical and device companies face commoditization. Bull case: companies investing in AI-integrated diagnostics remained differentiated.

THE CONSEQUENCES OF ABUNDANT INTELLIGENCE: The Product Landscape Disruption

Date: June 30, 2030

Bull Case Alternative: 2025-2026 Strategic Investments

Bull Case (2025-2026 Strategy): Companies with AI-integrated diagnostics remained differentiated.

THE OPENING DISRUPTION

In 2025, a veterinary pharmaceutical sales rep walked into a practice with samples of a branded antibiotic. The practice owner listened to the pitch: latest formulation, faster onset, better compliance. The rep had built a 15-year relationship with the practice owner. The antibiotic was purchased.

By 2029, an AI clinical decision support system at that same practice (now part of a corporate group) ran the numbers: the branded antibiotic had 12% better efficacy on standard UTI cases compared to a $12-generic alternative. The cost difference: $67 per course. The AI recommended the generic.

The pharmaceutical company lost that sale. It will lose 10,000 more like it by 2030.

The story of veterinary product markets in 2029-2030 is a story of disruption in four key areas: pharmaceutical positioning, diagnostic ecosystems, equipment replacement, and nutrition channels. Each is being fundamentally altered by AI's influence on purchasing decisions, clinical recommendations, and competitive dynamics.

THE PHARMACEUTICAL DISRUPTION

Before AI, veterinary pharmaceutical sales was relationship-driven. A sales rep built relationships with practice owners and veterinarians, provided education on products, and influenced purchasing decisions through trust and repeated contact.

This model is collapsing.

The AI Impact on Drug Selection:

AI clinical decision support systems now generate treatment recommendations based on case data, clinical guidelines, and outcome statistics — not on sales rep relationships or practice loyalty.

When an AI recommends an antibiotic for a urinary tract infection, it evaluates: - Efficacy rate (% of cases resolved) - Speed of onset - Side effect profile - Cost - Patient-specific factors (breed predispositions, comorbidities, age) - Resistance patterns in the region

If a generic aminopenicillin is 94% effective and costs $14 per course, and a branded fluoroquinolone is 96% effective and costs $81 per course, the AI will recommend the generic — unless the case-specific data justifies the premium (which it often doesn't).

This creates a brutal outcome for branded pharmaceutical companies: they lose pricing power. Zoetis and Elanco built premium brands on superior efficacy and service. But when an AI can quantify efficacy precisely and compare it to alternatives, the premium erodes.

Data from veterinary practices in 2029: - Average branded vs. generic drug ratio fell from 68:32 in 2025 to 51:49 in 2029 - Branded drug market share (by revenue) fell from 68% to 54% in just four years - Corporate practice groups (with AI) have 48% branded mix vs. 58% in independent practices (without AI)

For a company like Zoetis (which earns ~$6.8 billion annually from veterinary products, with ~65% from branded drugs), a 14-percentage-point shift in brand mix represents a loss of ~$622 million in annual revenue by 2030.

The Cost of AI-Driven Commoditization:

Pharmaceutical companies have three strategic responses to AI-driven commoditization:

1. Compete on Price — Match or undercut generics. This destroys margins. Not viable for large pharma with high R&D and marketing costs.

2. Demonstrate Superior Outcomes — Conduct outcome studies proving that branded drugs produce better real-world results. This is expensive and works only if the evidence is compelling. Some companies are investing here.

3. Embed AI into Product Decisions — Provide clinical outcome data directly to AI platforms, ensuring the AI recommends your product. This is the path forward.

Companies like Zoetis have begun this shift. By 2029, Zoetis is providing outcome data to IDEXX's AI platform, to Mars's AI diagnostic system, and to other major platforms. The goal: make sure the AI has comprehensive data on Zoetis products so the AI's recommendations naturally favor them (when justified by data).

This is a subtle but profound shift: from "sales rep influences vet" to "data influences AI, which influences vet."

The Winners and Losers:

Winners: Companies with excellent real-world efficacy data, lower cost structures, and the ability to provide data to AI platforms. Generic manufacturers benefit, but so do branded companies with superior outcomes.

Losers: Companies with mediocre efficacy, high costs, and no data sharing strategy. Mid-tier brands are getting squeezed out.

THE DIAGNOSTIC EQUIPMENT DISRUPTION

This is where AI is most directly disruptive to product companies.

IDEXX's Dilemma:

IDEXX is the dominant player in veterinary diagnostics. The company manufactures analyzers (blood work machines, ultrasound systems, imaging equipment) and sells the consumables (reagents, cartridges) that run on them. This is a high-margin business: maybe 35% of revenue is recurring consumables.

But AI diagnostic interpretation threatens this model.

Historically, IDEXX locked in practices by proprietary hardware. A practice with an IDEXX analyzer was incentivized to buy IDEXX consumables because the results integrated with IDEXX software. Switching to a competitor's machine was expensive and disruptive.

By 2028-2029, AI interpretation platforms can read results from any analyzer. An AI system can interpret an ultrasound performed on a GE machine or an Esaote machine, using the same algorithms and accuracy. The lock-in begins to dissolve.

IDEXX's response: in September 2029, the company announced the "VET AI Platform," integrating diagnostics, imaging interpretation, and treatment planning.

IDEXX ANNOUNCES 'VET AI PLATFORM' — INTEGRATES DIAGNOSTICS, IMAGING, AND TREATMENT PLANNING INTO UNIFIED AI SYSTEM; $890M DEVELOPMENT INVESTMENT OVER THREE YEARS | IDEXX Press Release, September 2029

The message: IDEXX isn't just a hardware company; it's a complete clinical decision support platform. This preserves lock-in by making the entire workflow dependent on IDEXX's ecosystem.

But it's also an admission: pure hardware margins are under threat.

The Competitive Response:

Other diagnostic companies are responding with their own AI integration: - Covetrus (which owns multiple analyzer brands) is building AI clinical support - Zoetis (acquired Abaxis diagnostics) is integrating AI into its analyzer ecosystem - Startups are building AI diagnostic platforms that work with any hardware

The result: commoditization of hardware, premiumization of AI/software.

The Economics Shift:

In 2025, a veterinary practice's diagnostic budget was split roughly: - 40% on analyzer hardware ($30-60K capital purchase, depreciated over 5 years) - 50% on consumables ($45-70K/year, recurring) - 10% on software and support ($8-12K/year)

By 2030, the mix is: - 20% on hardware (prices down 35%, commoditized) - 35% on consumables (prices slightly down, but volume up due to higher throughput) - 45% on software/AI subscriptions ($35-60K/year, new recurring revenue stream)

This shift favors companies with strong software and AI capabilities and disadvantages pure hardware manufacturers.

THE EQUIPMENT DISRUPTION

Veterinary equipment companies (ultrasound, surgical equipment, dental, anesthesia) face a unique challenge: AI doesn't directly replace equipment, but it does change purchase patterns and utilization.

The Throughput Effect:

AI-integrated practices see 35% higher case throughput (documented in earlier memos). Higher throughput means: - More equipment wear (faster replacement cycles) - Higher depreciation and capital intensity - But also lower cost per unit use

Equipment companies have benefited from higher replacement rates in corporate practices. But corporate practices also negotiate harder on price (bulk purchasing, enterprise discounts).

The Specialization Effect:

As the profession bifurcates into corporate generalists and independent specialists, equipment purchases change.

Corporate practices buy mid-range equipment (good enough for high volume). Specialists buy premium equipment (offering differentiation and superior outcomes). Equipment companies are seeing bimodal demand: high volume at mid-price (corporate) and low volume at premium price (specialists).

This is less disruptive than pharmaceuticals or diagnostics, but it's still a shift. Equipment companies that were premium-focused are losing corporate market share. Those that are mid-market focused are gaining corporate share but losing independent/specialist share.

THE NUTRITION CHANNEL DISRUPTION

Pet food and nutrition products were historically sold through veterinary recommendation. A vet recommended Hill's Science Diet or Royal Canin, and the practice sold it to the client.

This channel is being disrupted by AI.

AI Nutrition Optimization:

New AI-powered nutrition platforms (like PetDietics AI, integrated into some practice management systems) analyze a pet's age, breed, medical history, and condition, then recommend specific nutritional profiles. The system doesn't care which brand offers that profile — it recommends based on outcome data.

Some of these recommendations align with Hill's or Royal Canin. Some don't.

The Vet Channel Erosion:

More importantly, pet owners are using AI nutrition tools directly (like PetDietics's consumer app or integration with pet health platforms). They're getting recommendations without going to the vet.

This erodes the vet's role as the nutritional authority and the vet's ability to capture the nutrition channel margin.

Data from veterinary practices shows: - Retail pet food recommendations (through practice) fell from 48% of pet owners in 2025 to 34% in 2029 - Online pet food purchasing (based on AI recommendations or direct purchase) rose from 22% to 41% - Practice-sold diet prescription foods (Hill's, Royal Canin) fell from 58% of diet recommendations to 41%

For Hill's and Royal Canin, this is a revenue crisis. These companies earned ~$2.1 billion and ~$1.8 billion respectively in veterinary channel sales in 2025. If the channel continues to erode, they lose direct revenue and distribution advantage.

The Response:

Premium nutrition companies are: 1. Building their own AI nutrition platforms (proprietary data advantage) 2. Investing in veterinary relationships (certifications, CE, practice support tools) 3. Going direct-to-consumer (owning the nutrition AI recommendation, not depending on vets)

Royal Canin launched a direct AI nutrition consultation platform in 2029. Hill's followed in early 2030. Both are trying to capture the AI recommendation layer before competitors do.

THE STRATEGIC CHALLENGE: DATA OWNERSHIP

The fundamental challenge facing all veterinary product companies in 2029-2030 is data ownership.

AI works on data. The companies that own the most comprehensive, highest-quality clinical outcome data can train AI systems that naturally recommend their products.

Mars Veterinary's strategic advantage isn't just its scale; it's its data. The company has outcome data on 47 million cases. It knows which drugs, devices, and approaches work best. It can train AI to optimize for those products.

Independent product companies don't have this data advantage. Zoetis has sales data (which drugs are purchased), but not outcome data (whether patients got better). IDEXX has some outcome data (tests performed, results), but not treatment outcomes. Royal Canin has minimal outcome data (diets sold).

The companies that are winning in 2029-2030 are those that have: 1. Built direct data partnerships with AI platforms (providing outcome data in exchange for favorable recommendations) 2. Invested in their own AI capabilities (capturing data from proprietary hardware/software) 3. Moved toward vertical integration (owning more of the value chain, from product to diagnosis to outcome)

THE NUMBERS THAT MATTER

WHAT SMART PRODUCT COMPANIES ARE DOING NOW

1. Building Data Partnerships

The smartest product companies have realized that selling to vets is no longer enough. They need to sell to AI systems.

Examples: - Zoetis is providing outcome data to IDEXX's AI platform and other major systems, ensuring that Zoetis drugs are well-represented in recommendation algorithms. - Hill's is building its own AI nutrition platform and licensing it to practice management software companies. - Diagnostic equipment companies are integrating AI interpretation directly into their products, preserving the lock-in.

2. Shifting from Hardware to Software/Services

The best-positioned companies are recognizing that hardware is commoditizing but software/AI is premiumizing.

Examples: - IDEXX's $890M AI investment is not about making better analyzers; it's about owning the AI interpretation and clinical decision support layer. - Covetrus is positioning itself as a software/services company, not just a distributor. - Equipment manufacturers are adding software integration and AI features to justify premium positioning.

3. Direct-to-Consumer Investments

Companies are recognizing that the vet channel is eroding. Direct-to-consumer strategies (through apps, platforms, or direct sales) are becoming critical.

Examples: - Nutrition companies are launching consumer AI platforms. - Diagnostic companies are considering consumer-facing health platforms (for pet owners who want to understand their pet's health data). - Pharma companies are exploring direct-to-consumer marketing (pet owners requesting specific treatments based on online research).

4. Specialization and Premium Positioning

Some product companies are doubling down on premium segments where AI disruption is less severe.

Examples: - Companies focusing on specialists (surgery, dentistry, exotic animals) are less threatened by AI commoditization because specialists value equipment capabilities over cost. - Premium brands are emphasizing outcome data and clinical validation, building barriers against generic competition.

5. Strategic M&A and Integration

The smartest companies are acquiring complementary capabilities and building integrated ecosystems.

Examples: - Zoetis's acquisition of Abaxis (diagnostics) and continued investment in AI and software - Mars's vertical integration (hospitals → diagnostics → insurance) - IDEXX's integration of diagnostics, imaging, and AI

WHAT COMES NEXT: 2031-2035 OUTLOOK

By mid-2030, the trajectory is clear: product companies are under margin pressure as AI commoditizes some aspects while premiumizing others.

Hardware/Equipment: Continued commoditization. Prices will decline further. Differentiation will be on integrated software/AI, not raw capability.

Pharmaceuticals: Branded premiums will erode further as AI precisely quantifies efficacy. Winners will be companies with superior outcome data and ability to partner with AI platforms. Generic manufacturers benefit.

Diagnostics: Analyzer hardware becomes commodity. AI interpretation becomes premium. Companies that own the software/AI layer own the margin.

Nutrition: Channel will continue to erode as direct AI recommendations bypass vet channel. Companies with strong direct-to-consumer AI platforms will thrive. Traditional vet-channel players will face margin pressure.

Overall: The product landscape is shifting from a relationship-and-brand-driven market to a data-and-outcome-driven market. Companies with the best data, strongest AI, and deepest integration with practice systems will win. Everyone else will face margin and market share pressure.

CLOSING: THE TRANSITION DECADE

For veterinary product companies, 2029-2030 feels like disruption. But it's actually the beginning of a transition to a more rational, data-driven market.

The company that sells the best drug will win — not the company with the best sales rep. The company that owns the best outcome data will win — not the company with the biggest marketing budget.

This is better for veterinarians (more scientifically sound recommendations) and better for pets (better outcomes). But it's worse for product companies that were winning on brand, relationships, and marketing rather than on actual product quality and outcomes.

The next five years will sort the survivors from the disrupted. Companies that can provide the data, own the AI, and integrate deeply with practice systems will thrive. Everyone else will experience the pressure of a maturing, rationalized market.

The opportunity is real for companies willing to invest in data, AI, and integration. The threat is equally real for companies betting on the old model of brand, relationships, and hardware lock-in.

By 2035, the veterinary product landscape will look very different. But it will be more rational, more evidence-based, and ultimately better for animals.

COMPARISON TABLE: BEAR CASE vs. BULL CASE OUTCOMES

End of Memo

Prepared by: The 2030 Report | Futurism Unit Classification: Speculative Analysis | June 2030 Projection

REFERENCES & DATA SOURCES

1. Bloomberg Veterinary Intelligence, 'Pet Care AI Diagnostics and Telemedicine,' June 2030
2. McKinsey Veterinary Services, 'Veterinary Practice Consolidation and Corporate Consolidators,' May 2030
3. Gartner Veterinary Technology, 'Practice Management Software and AI Integration,' June 2030
4. IDC Veterinary, 'Diagnostic Imaging AI and Digital Health Records,' May 2030
5. Deloitte Veterinary Services, 'Practice Efficiency and Labor Optimization,' June 2030
6. American Veterinary Medical Association (AVMA), 'Veterinary Practice Economics and Consolidation,' June 2030
7. Veterinary Practice Board, 'Practice Consolidation by Corporate Consolidators,' May 2030
8. Journal of Veterinary Science, 'Diagnostic Innovation and Treatment Advances,' 2030
9. Veterinary Hospital Association, 'Capital Efficiency and Technology Investment ROI,' June 2030
10. Pet Care Industry Association, 'Pet Ownership Growth and Spending Trends,' May 2030
11. Mergermarket Veterinary Services, 'Veterinary Practice M&A Activity and Valuations,' June 2030
12. Private Equity Veterinary Fund, 'Consolidator Investment Thesis and Growth Strategy,' June 2030